18F-fallypride PET of pancreatic islets: In vitro and in vivo rodent studies

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1125-1132

  Garcia, Adriana ^a,b   Mirbolooki, Mohammad Reza ^a   Constantinescu, Cristian ^a   Pan, Min Liang ^a   Sevrioukov, Evegueni ^a   Milne, Norah ^a   Wang, Ping H ^a,b   Lakey, Jonathan ^a   Chandy, K George ^b   Mukherjee, Jogeshwar ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F fallypride; Diabetes; Islet cells; Pancreas; PET

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE F 18; HALOPERIDOL; INSULIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EX VIVO STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SPLEEN; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; FEASIBILITY STUDY; METABOLISM; METHODOLOGY; RADIOGRAPHY; SCINTISCANNING; SPRAGUE DAWLEY RAT; TRANSPLANTATION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BENZAMIDES; BIOLOGICAL TRANSPORT; DIABETES MELLITUS, EXPERIMENTAL; FEASIBILITY STUDIES; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SPLEEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960308067     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088583     Document Type: Article

References (34)

1. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes. Diabetes. 2008;57:2883-2888.
2. Wajchenberg BL. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol. 2010;654:515-535.
3. Wu Z, Kandeel F. Radionuclide probes for molecular imaging of pancreatic betacells. Adv Drug Deliv Rev. 2010;62:1125-1138.
4. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest. 2006;116:1506-1513.
5. Singhal T, Ding YS, Weinzimmer D, et al. Pancreatic beta cell mass PET imaging and quantification with 11C-DTBZ and 18F-FP-(+)-DTBZ in rodent models of diabetes. Mol Imag Biol. September 8, 2010 [Epub ahead of print].
6. Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr. 2007;150:140-145. (Pubitemid 46127552)
7. Sperling MA. PET scanning for infants with HHI: a small step for affected infants, a giant leap for the field. J Pediatr. 2007;150:122-124. (Pubitemid 46107984)
8. Sweet IR, Cook DL, Lernmark A, et al. Systemic screening of potential b-cell imaging agents. Biochem Biophys Res Commun. 2004;314:976-983. (Pubitemid 38142379)
9. Rubí B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280:36824-36832. (Pubitemid 41587763)
10. 18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol. 1995;22:283-296.
11. Mukherjee J, Shi B, Christian BT, Chattopadhyay S, Narayanan TK. 11C-fallypride: radiosynthesis and preliminary evaluation of novel dopamine D2/D3 receptor PET radiotracer in nonhuman primate brain. Bioorg Med Chem. 2004;12:95-102. (Pubitemid 38096221)
12. Constantinescu C, Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol. 2009;54:2885-2899.
13. Cheng Y, Zhang JL, Liu YF, Li TM, Zhao N. Islet transplantation for diabetic rats through the spleen. Hepatobiliary Pancreat Dis Int. 2005;4:203-206. (Pubitemid 40790166)
14. Islam MS, Loots du T. Experimental rodent models of type 2 diabetes: a review. Methods Find Exp Clin Pharmacol. 2009;31:249-261.
15. Willekens I, Lahoutte T, Buls N, et al. Time course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC. Mol Imaging Biol. 2009;11:128-135.
16. Rajab A. Islet transplantation: alternative sites. Curr Diab Rep. 2010;10:332-337.
17. Kaufman DB, Morel P, Field MJ, et al. Purified canine islet autografts: functional outcome as influenced by islet number and implantation site. Transplantation. 1990;50:385-391. (Pubitemid 20309856)
18. Aoki T, Hui H, Umehara Y, et al. Intrasplenic transplantation of encapsulated genetically engineered mouse insulinoma cells reverses streptozotocin-induced diabetes in rats. Cell Transplant. 2005;14:411-421. (Pubitemid 41324372)
19. Van Laere K, Varrone A, Booij J, et al. EANM procedure guidelines for brain transmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:434-442.
20. Garcia-Tornadu I, Perez-Millan MI, Recouvreux V, et al. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2-/- mouse. Neuroendocrinology. 2010;92:207-214.
21. Grossrubatscher E, Veronese S, Dalino P, et al. High expression of dopamine receptor subtype 2 in a large series of neuroendocrine tumors. Cancer Biol Ther. 2008;7:1970-1978.
22. Shankar E, Santosh KT, Paulose CS. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life. 2006;58:157-163. (Pubitemid 43786041)
23. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170-188. (Pubitemid 35155170)
24. Mukherjee J, Yang ZY, Brown T, et al. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and non-human primate brains using the high affinity radioligand, [F-18]fallypride. Nucl Med Biol. 1999;26:519-527.
25. 18F-desmethoxyfallypride. Synapse. 2011;65:778-787.
26. Fagerholm V, Mikkola KK, Ishizu T, et al. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med. 2010;51:1439-1446.
27. 11C-DTBZ, a monoamine vescicular transporter inhibitor in healthy human subjects. J Nucl Med. 1999;40:283-289.
28. Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-1330. (Pubitemid 44465460)
29. Medarova Z, Vallabhajosyula P, Tena A, et al. In vivo imaging of autologous islet grafts in the liver and under the kidney capsule in non-human primates. Transplantation. 2009;87:1659-1666.
30. Kim SJ, Doudet DJ, Studenov AR, et al. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med. 2006;12:1423-1428. (Pubitemid 44924502)
31. Pattou F, Kerr-Conte J, Wild D. GLP-1 receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363:1289-1290.
32. Low G, Hussein N, Owen RJ, et al. Role of imaging in clinical islet transplantation. Radiographics. 2010;30:353-366.
33. Medarova Z, Evgenov NV, Dai G, Bonner-Weir S, Moore A. In vivo multimodal imaging of transplanted pancreatic islets. Nat Protoc. 2006;1:429-435.
34. Eriksson O, Eich T, Sundin A, et al. Positron emission tomography in clinical islettransplantation. Am J Transplant. 2009;9:2816-2824.